Anthera Pharmaceuticals Inc. (ANTH)

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Clinical-stage program includes a Phase 2, blisibimod study. Blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others.

COMPANY ADDRESS
25801 Industrial Blvd.
Suite B
Hayward, CA 94545
United States

COMPANY PHONE
510-856-5600

COMPANY WEBSITE



Get BioInvest's perspective on Anthera's CEO


Latest Company News

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Departure of ... Market Exclusive - 9 hours ago Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. [...]
Thu, Apr 27, 2017 8:26:00 PM, Continue reading at the source
Sales Growth Analysis: Anthera Pharmaceuticals, Inc. (ANTH), Select Comfort ... USA Commerce Daily - 13 hours ago Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) observed rebound of 4.32% since bottoming out at $0.361 on Apr. 07, 2017. [...]
Thu, Apr 27, 2017 5:03:00 PM, Continue reading at the source
Anthera Pharmaceuticals, Inc. (ANTH) closed at $0.38 in the last trading session TopChronicle - 17 hours ago The share of Anthera Pharmaceuticals, Inc. (ANTH) currently has a value of $0.38 while the company's 52 week low is at $0.36, the shares dropped to the 52 week low on 04/07/17. Anthera Pharmaceuticals, Inc. (ANTH) has a 52-Week High of $4.37 - StandardOracle Most Active Volume Stock: Anthera Pharmaceuticals, Inc. (ANTH) - HugoPress [...]
Thu, Apr 27, 2017 12:55:00 PM, Continue reading at the source
Anthera Pharmaceuticals, Inc. (ANTH) hit his 1-Year Low price on 04/07/17 TopChronicle - Apr 26, 2017 The share of Anthera Pharmaceuticals, Inc. (ANTH) currently has a value of $0.38 while the company's 52 week low is at $0.36, the shares dropped to the 52 week low on 04/07/17. [...]
Wed, Apr 26, 2017 11:26:00 AM, Continue reading at the source
Hot Stocks Report: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Cliffs Natural ... Post Analyst - Apr 25, 2017 The earnings of Cliffs Natural Resources Inc. (CLF) are forecasted by the analysts to move at $0.17 in current quarter, from $0.62 a year-ago quarter. [...]
Tue, Apr 25, 2017 7:41:00 PM, Continue reading at the source
Why to Keeping Eye on SunCoke Energy, Inc. (SXC), Anthera Pharmaceuticals, Inc ... StockNewsJournal - Apr 25, 2017 Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), maintained return on investment for the last twelve months at -211.50, higher than what Reuters data shows regarding industry's average. [...]
Tue, Apr 25, 2017 6:56:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Is Getting Cheaper: Is It Still ... Insider Financial - Apr 17, 2017 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is one we've looked at a couple of times in the past, and one we've taken something of a contrarian position on as a result of this coverage. Taking a Fresh Look at Anthera Pharmaceuticals, Inc. (ANTH) - StockNewsJournal Stock to Watch For: Anthera Pharmaceuticals, Inc. (ANTH) - StandardOracle [...]
Mon, Apr 17, 2017 6:56:00 PM, Continue reading at the source
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) May Be Headed To The Right Direction ... Journal Transcript - Apr 3, 2017 Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has today made public the findings it obtained from the Extension Period of the Phase 3 SOLUTION, non-inferiority clinical study in cystic fibrosis among patients struggling with exocrine pancreatic insufficiency . Critical Chart Information For Anthera Pharmaceuticals, Inc. (ANTH) - NY Stock News Anthera Pharmaceuticals, Inc. (ANTH) traded with volume of 1.56 Million shares ... - StandardOracle [...]
Mon, Apr 03, 2017 10:48:00 AM, Continue reading at the source
Analyst's Predictions on QEP Resources, Inc. (QEP), Anthera Pharmaceuticals ... StockNewsJournal - Mar 31, 2017 Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), maintained return on investment for the last twelve months at -211.50, higher than what Reuters data shows regarding industry's average. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Other Events - Market Exclusive Anthera Pharmaceuticals Inc. (ANTH) Moves Lower on Volume Spike for March 31 - Equities.com [...]
Fri, Mar 31, 2017 12:56:00 PM, Continue reading at the source
Anthera Pharmaceuticals Now Trading Below Cash Value. This Biotech Could Rise ... Seeking Alpha - Feb 22, 2017 Because of this, I love buying beaten-down biotech stocks that still have lots of upside potential as well as very strong, cash-rich balance sheets. Anthera Pharmaceuticals Inc (NASDAQ:ANTH): Ignore The Lawsuits - Insider Financial [...]
Wed, Feb 22, 2017 5:57:00 PM, Continue reading at the source